

**10/579006**  
**1AP20 Rec'd PCT/PTO 11 MAY 2006**

Docket No.: CCI-067US  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Campbell McInnes *et al.*

International Application No.: PCT/GB2004/004762

Confirmation No.: N/A

International Filing Date: November 12, 2004

Application No.: NEW APPLICATION

Filed: Concurrently Herewith

Art Unit: N/A

For: METHOD FOR IDENTIFYING INHIBITORS  
USING A HOMOLOGY MODEL OF POLO-  
LIKE KINASE 1

---

Examiner: Not Yet Assigned

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith. Accordingly, Applicant believes that no additional fees are necessary with the filing of this Statement.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Application No.: National Phase of PCT/GB2004/004762

Docket No.: CCI-067US

10/579006

AP2006dPG/PTO 11 MAY 2006

Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CCI-067US.

Dated: May 11, 2006

CLK/MXG/mch

Respectfully submitted,

By 

Cynthia L. Kanik, Ph.D.

Registration No.: 37,320

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant

AP20 Rec'd PCT/PTO 11 MAY 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Campbell MCINNES
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	CCI-067US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	WO-99/09146-A1	02-25-1999	Smithkline Beecham Corporation		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Accession No. AAU74656, "Mammalian polo-like kinase (Plk)," dated April 9, 2002	
	C2	Accession No. P53350, "Serine/threonine-protein kinase PLK1 (EC 2.7.1.37) (Polo-like kinase 1) (PLK-1) (Serine/Threonine-protein kinase 13)," dated October 1, 1996	
	C3	Accession No. Q59GD0, "Polo-Like Kinase Variant," dated May 10, 2005	
	C4	Elia, Andrew E.H. et al, "The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Plks by the Polo-Box Domain," <i>Cell</i> , Vol. 115:83-95 (2003)	
	C5	Liu, Xiaoqi et al, "Polo-Like Kinase 1 in the Life and Death of Cancer Cells," <i>Cell Cycle</i> , Vol. 2(5):424-425 (2003)	
	C6	Roshak, Amy K. et al, "The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase," <i>Cellular Signalling</i> , Vol. 12:405-411 (2000)	
	C7	Stevenson, Christopher S. et al, "The Identification and Characterization of the Marine Natural Product Scytonemin as a Novel Antiproliferative Pharmacophore," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 303(2):858-866 (2002)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--